Table 4.
Effects of bortezomib on renal function and proteinuria in LPK rats.
| Parameter | LPK+Vehicle (week 6) N = 3 | LPK+BTZ (week 6) N = 3 | LPK+Vehicle (week 10) N = 8 | LPK+BTZ (week 10) N = 9 |
|---|---|---|---|---|
| Final BW | 146 ± 16 | 139 ± 23 | 192 ± 16 | 188 ± 12 |
| HW:BW (%) | – | – | 0.496 ± 0.04 | 0.504 ± 0.04 |
| Urine Pr:Cr (mg/mmol) | 11 ± 4 | 11 ± 4 | 138 ± 58 | 105 ± 58 |
| 24‐h urine volume (mL) | 5 ± 2 | 5 ± 3 | 20 ± 5 | 20 ± 6 |
| Serum urea (mmol/L) | 6 ± 2 | 8 ± 3 | 12 ± 2 | 14 ± 3 |
| Serum Cr (μmol/L) | 22 ± 2 | 26 ± 2* | 35 ± 2 | 39 ± 5† |
| Serum Albumin (g/L) | 26 ± 1 | 25 ± 1 | 28 ± 2 | 26 ± 2 |
| CrCl/BW (μL/min/g BW) | 5.1 ± 0.7 | 4.4 ± 0.9 | 4.5 ± 0.6 | 4.1 ± 0.5 |
BW, body weight; BTZ, bortezomib; Cr, creatinine; CrCl/BW, creatinine clearance corrected for body weight; LPK, Lewis polycystic kidney; HW:BW, heart weight to body weight ratio; Pr:Cr, urinary protein to creatinine ratio.
Data expressed as mean ± SD.
*P < 0.05 versus Lewis + vehicle (week 6), †P < 0.05 versus LPK + vehicle (week 10).